Abstract
There is evidence that calcitriol is the only biologically active vitamin D metabolite. This review summarizes data on the regulation of renal and extrarenal synthesis of calcitriol by nutritional, physiologic, mechanical, genetic, and disease-related factors. Relatively low circulating calcitriol due to low substrate availability, i.e., low circulating 25-hydroxyvitamin D, has been reported in nutritional rickets, osteomalacia, obesity, and preeclampsia. In these situations, vitamin D supplementation can increase circulating calcitriol and, together with calcium, prevent rickets/osteomalacia and reduce the risk of preeclampsia and obesity-related type 2 diabetes mellitus. However, the correction of low circulating calcitriol due to mechanical unloading/immobilization by vitamin D supplementation is not effective in preventing osteoporotic fractures. Circulating calcitriol is also low in diseases such as cardiac and renal failure. Both illnesses share some other similarities regarding dysregulated calcium/phosphate metabolism, including elevated parathyroid hormone and fibroblast growth factor-23, suggesting similar treatment strategies. Genetic disorders of vitamin D metabolism are rare and can affect circulating calcitriol differently. Calcitriol synthesis in immune cells is obviously not primarily dependent on circulating 25-hydroxyvitamin D, which challenges the use of vitamin D for infection prevention. Since various factors can differently influence calcitriol regulation, more personalized preventive/therapeutic strategies of targeting calcitriol synthesis are necessary.